Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | FLT1 | P17948 | 3/20 | 0.41 |
| ▸ | FLT4 | P35916 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5799233 | 0.95 | CYP19A1 (0.45) | CYP19A1S1PR4CHRNB4CHRNA3MAOA | |
| SCHEMBL19462043 | 0.87 | DRD4 (0.52) | CYP19A1CHRNB4CHRNA3MAOAMAOB | |
| SCHEMBL8791874 | 0.87 | DRD4 (0.52) | CYP19A1CHRNB4CHRNA3MAOAMAOB | |
| SCHEMBL13419646 | 0.87 | S1PR4 (0.50) | CYP19A1S1PR4CHRNB4CHRNA3HRH3 | |
| SCHEMBL22069747 | 0.85 | CYP19A1 (0.59) | CYP19A1S1PR4SIGMAR1HSPB1 | |
| SCHEMBL2551985 | 0.83 | S1PR4 (0.54) | CYP19A1S1PR4SIGMAR1HSPB1 | |
| SCHEMBL13419616 | 0.82 | SCN9A (0.59) | CYP19A1S1PR4 | |
| SCHEMBL13419606 | 0.81 | CYP19A1 (0.44) | CYP19A1S1PR4CHRNB4CHRNA3HSPB1 | |
| SCHEMBL3190605 | 0.81 | SIGMAR1 (0.61) | CHRNB4CHRNA3MAOAMAOBHRH3 | |
| SCHEMBL13419327 | 0.81 | MAOA (0.46) | MAOAMAOBEGFRFGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| EP-1682531-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1654238-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050107374-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005042518-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005009978-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | CYP19A1 434/4885S1PR4 1608/4885CHRNB4 1691/4885 |
| US-20050107374-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | CYP19A1 923/4885S1PR4 1399/4885CHRNB4 1960/4885 |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | STAT6, RELA, NFKB2 | CYP19A1 2196/4885S1PR4 1589/4885CHRNB4 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.